








JewelACL™

The Tissue Graft Sparing
Device for Anterior Cruciate
Ligament Reconstruction



Why JewelACL?

- Can be implanted either as a stand alone device to eliminate graft morbidity (total tissue graft sparing), or with a single hamstring tendon to reduce morbidity (partial tissue graft sparing).
- Secured to the bone with cortical suspensory fixation with loop or soft threaded interference screws. (See LAB 138, **JewelACL** Surgical Technique Manual, and WP 006, Mechanical Properties and Performance Testing of the **JewelACL**, for additional information).
- Implanted using standard contemporary cruciate reconstruction drill guide systems.
- Surfaces of the implant are modified with a unique gas plasma treatment process that renders the **JewelACL** hydrophilic.
- The **JewelACL** is integrated in natural body tissue that surrounds the device and occupies the spaces within it.




The information above **MUST NOT** be used to perform the surgical procedure.
Always refer to the Instructions for Use LAB 139 which contains detailed information and essential warnings and precautions.

Ordering Information

Implant:

102-6003 **JewelACL™**, 7 mm ID x 710 mm (supplied sterile)



Get Involved

At Xiros we are constantly striving to improve outcomes for patients, and we want to hear from you. Help us create the future of sports medicine and share your opinions and expertise with us at: www.xiros.co.uk

Developed and manufactured by

[Xiros™ Ltd](http://www.xiros.co.uk)

Springfield House, Whitehouse Lane, Leeds LS19 7UE

Tel. +44 (0) 113 238 7202 Fax. +44 (0) 113 238 7201

enquiries@xiros.co.uk

www.xiros.co.uk

Xiros Limited, registered in England No. 1664824.

Xiros and **JewelACL** are trademarks of Xiros.

All rights reserved. © Xiros™ 2023. Worldwide patents and patents pending.